bleau 3) impliquant un faible risque.
également insuffisant, on peut envisa-
ger un soutien médicamenteux. Pour
un aperçu des preuves scientifiques
et des recommandations internatio-
nales, nous vous renvoyons au ta-
bleau 5. Dans un souci d'exhaustivité,
nous vous présentons également un
aperçu des preuves scientifiques et
des recommandations pour les pa-
tients souffrant d'un trouble bipolaire.
actuelle relative à l'augmentation du
risque d'affections cardiométaboliques
chez les sujets dépressifs, on a tout intérêt
à bien suivre le fonctionnement somatique
des patients dépressifs, surtout en cas d'uti-
lisation prolongée d'ATC et d'antipsycho-
tiques. En cas d'anomalies métaboliques,
il faut en premier lieu adresser le patient à
des soins plus spécialisés. Si ces soins
s'avèrent insuffisants, il faut envisager de
changer d'antidépresseur ou d'antipsycho-
tique, ou encore envisager un soutien mé-
dicamenteux complémentaire.
1.
men van depressie in België. Stand van zaken en reflec-
ties voor de toekomst. Tijdschr Psychiatrie 2008;
50(10):655-65.
years (DALYs) for 291 diseases and injuries in 21 regions,
1990-2010: a systematic analysis for the Global Burden
of Disease Study 2010. Lancet 2012;380(9859):2197-223
disease. A review and meta- analysis Am J Prev Med
2002;23:51-61.
syndrome and metabolic abnormalities in patients with
major depressive disorder: a meta-analysis of prevalences
and moderating variables. Psychol Med 2013; geaccept-
eerd voor publicatie.
ditions mediate the association between depression and
cardiovascular disease mortality. Soc Psychiatry Psychiatr
Epidemiol 2012;47(4):615-25.
pressive disorder predicts completion, adherence, and
outcomes in cardiac rehabilitation: a prospective cohort
study of 195 patients with coronary artery disease. J Clin
Psychiatry 2011;72(9):1181-8.
pressive syndromes be reclassified as «metabolic syn-
drome type II»? Ann Clin Psychiatry 2007;19(4): 257-64.
pathophysiologic
cal analysis. Biol Psychol 2007;74:200-11.
DH, McConnell H. Mind and heart: heart rate variability
in major depressive disorder and coronary heart disease
- a review and recommendations. Aust N Z J Psychiatry
2012;46(10):946-57.
itary-adrenal activation: a quantitative summary of four
decades of research. Psychosom Med 2011;73(2):114-26.
Cortisol responses to mental stress and the progression of
coronary artery calcification in healthy men and women.
PLoS One 2012;7(2):e31356.
analysis of cytokines in major depression. Biol Psychiatry
2010;67:446-57.
sion: A systematic review and meta-analysis of longitudi-
nal studies.. J Affect Disord 2013; doi:pii: S0165-
0327(13)00477-1. 10.1016/j.jad.2013.06.004.
factor alpha (TNF-) and soluble interleukin-2 receptors
(sIL-2R) are elevated in patients with major depressive
disorder: a meta-analysis and meta-regression. J Affect
Disord 2012;139(3):230-9.
853-9.
platelet function, and ischemic heart disease. Psychosom
Med 2005;67(Suppl 1):34-6.
genetic factors in the co-occurrence of symptoms of de-
pression and cardiovascular risk factors. J Affect Disord
2010;122(3):247-52.
cial factors, and genetics: the case of depression. Prog
Cardiovasc Dis 2013;55(6):557-62.
immune genes in the association between depression and
inflammation: a review of recent clinical studies. Brain
Behav Immun 2013;31:31-47.
bruik van antidepressiva en Antipsychotica. 2013; Rijk-
sinstituut voor ziekte- en invaliditeitsverzekering. Website
http://www.riziv.be/information/nl/studies/study61/pdf/
studie61.pdf geraadpleegd op 21 augustus 2013.
lines in America and Europe. J Clin Psychiatry 2010;
71(Suppl E1):e04.
sants needed for psychotic depression? A systematic re-
view and meta-analysis of trials comparing antidepres-
sant or antipsychotic monotherapy with combination
treatment. J Clinical Psychiatry 2012;73(4):486-96.
tween conventional antidepressants and the metabolic
syndrome: a review of the evidence and clinical implica-
tions. CNS Drugs. 2010;24(9):741-53.
patients with severe mental disorders. I. Prevalence, im-
pact of medications and disparities in health care. World
Psychiatry 2011;10:52-77.
cal care for people with and without comorbid mental
illness and substance misuse: systematic review of com-
parative studies. Br J Psychiatry 2009;194(6):491-9.
handeling van cardiovasculaire risicofactoren bij behan-
deling met antipsychotische medicatie. Neuron
2012;17(5):1-6.
disease and diabetes in people with severe mental illness
position statement from the European Psychiatric Associ-
ation (EPA), supported by the European Association for
the Study of Diabetes (EASD) and the European Society of
Cardiology (ESC). Eur Psychiatry 2009;24(6):412-24.
guidelines on cardiovascular disease prevention in clini-
cal practice: executive summary. Eur J Cardiovasc Prevent
Rehabil 2007;14(Suppl 2):E1-E40.
en met antipsychotica: screening en follow-up. Neuron
2013;18(1):1-5.
nadian Network for Mood and Anxiety Treatments (CAN-
MAT) task force recommendations for the management of
patients with mood disorders and comorbid metabolic
disorders. Ann Clin Psychiatry 2012;24(1):69-81.
patients souffrant d'un trouble bipolaire et de dépression majeure (31).
Trouble bipolaire